Aprea Therapeutics Q1 net loss narrows as R&D expenses fall

Overview

• US precision oncology firm's Q1 net loss narrowed yr/yr as R&D expenses declined

• Cash and cash equivalents rose to $46.5 mln after $30 mln private placement

• Company observed two partial responses in ongoing Phase 1 APR-1051 trial

Outlook

• Company anticipates cash runway into Q1 2028

Result Drivers

• R&D EXPENSES - Decrease in research and development costs mainly due to pausing the ABOYA-119 trial evaluating ATRN-119

Company press release: ID:nGNX71cR2N

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Aprea Therapeutics Inc is $5.00, about 455.6% above its May 12 closing price of $0.90

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.